TScan Therapeutics, Inc (TCRX) IPO Opens 20% Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
TScan Therapeutics, Inc (TCRX) Price 6.7M Share IPO at $15/sh
July 16, 2021 5:00 AM EDTTScan Therapeutics, Inc. (NASDAQ: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $100.0 million, before underwriting discounts, commissions, and offering expenses payable by TScan. In addition, TScan has granted the underwriters an option for a period of 30 days to purchase up to 1,000,000 additional shares of common stock... More



